Status:
COMPLETED
Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Social Anxiety Disorder
Eligibility:
All Genders
8-17 years
Phase:
PHASE3
Brief Summary
To determine the anxiolytic efficacy, safety, and tolerability of a flexible-dose of venlafaxine extended release (ER) administered for 16 weeks in the treatment of children and adolescent outpatients...
Eligibility Criteria
Inclusion
- Male or female outpatient
- 8-17 year old
- diagnosis of Social Anxiety Disorder
Exclusion
- concomitant psychiatric or medical disorders which interfere with safety or assessment
Key Trial Info
Start Date :
December 1 1999
Trial Type :
INTERVENTIONAL
End Date :
June 1 2003
Estimated Enrollment :
293 Patients enrolled
Trial Details
Trial ID
NCT00238719
Start Date
December 1 1999
End Date
June 1 2003
Last Update
May 19 2006
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.